Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety
Johannes Hauser, Jan Sarlon, Timur Liwinski, Annette B Brühl, Undine E. Lang
Frontiers in Psychiatry January 23, 2024 DOI: 10.3389/fpsyt.2024.1327598 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 37 |
| Population | Patients with therapy-resistant depression receiving intranasal (es)ketamine |
| Intervention | listening to music during intranasal (es)ketamine administration |
| Topics | Anxiety Depression Esketamine Ketamine |
| Citations | 10 |
| Key findings | Listening to music during intranasal (es)ketamine therapy is associated with reduced anxiety, lower blood pressure, stable dissociation, and tolerance for higher doses. |
Abstract
BackgroundAlthough the effectiveness of (es)ketamine for therapy-resistant depression (TRD) has been established, potential treatment-limiting factors include side effects like dissociation, anxiety, or elevated blood pressure. Music can reduce stress and negative emotions as anxiety. This study aimed to investigate the impact of listening to music during intranasal (es)ketamine administration on both tolerability and efficacy.MethodsRecords of 494 sessions (of 37 patients) with intranasal (es)ketamine administration, each containing data of blood pressure measurements, DSS-IV (dissociation symptoms scale-IV), anxiety and euphoria analogue scale, MADRS (Montgomery–Åsberg Depression Rating Scale) and BDI (Beck’s Depression Inventory) were evaluated.ResultsThe between-group analysis, comparing participants who listened to music with those who did not, revealed significant differences in the administered dose (p-value: 0.003, mean: 131.5 mg with music vs. 116.7 mg without music), scores on the DSS Item 1 (p-value: 0.005, mean: 3 points vs. 2.4 points), levels of anxiety (p-value: <0.001, mean: 0.4 points vs. 1.4 points), and measurements of maximal systolic blood pressure after administration (p-value: 0.017, mean: 137.9 mmHg vs. 140.3 mmHg). Listening to music had no impact on the MARDS-change score between the sessions.LimitationsKey limitations include a non-randomized naturalistic design and the non-standardized selection of music, which was based on individual patient preferences.ConclusionListening to music during intranasal (es)ketamine therapy appears to be linked to reduced anxiety and lower blood pressure, stable or increased dissociation levels, and improved tolerance for higher doses. These findings could potentially contribute to the optimization of (es)ketamine therapy, both in terms of treatment efficacy and managing side effects.
Comparable studies
Other observational and cohort studies on ketamine for anxiety, most cited first.
Citations in the library
Cited by 3
- The Role of Music in Psychedelic-Assisted Therapy: A Comparative Analysis of Neuroscientific Research, Indigenous Entheogenic Ritual, and Contemporary Care Models. Psychedelic Medicine December 2, 2024
- Effects of Binaural Beat Music and Esketamine for ECT in the Treatment of Major Depressive Disorder: A Randomized Controlled Trial Protocol. Neuropsychiatric Disease and Treatment 2025
- The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant Depression. Current Neuropharmacology April 7, 2025
Cites 5
- LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp May 6, 2016
- The hidden therapist: evidence for a central role of music in psychedelic therapy Psychopharmacology February 1, 2018
- A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties. Journal of psychopharmacology (Oxford, England) August 1, 2021
- Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications Journal of Music Therapy 2020
- An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression. Frontiers in Psychiatry November 24, 2021